Last updated: February 19, 2026
Licart (chemical name: AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by AstraZeneca. It targets specific EGFR mutations, including T790M, a common resistance mechanism that emerges after treatment with earlier-generation EGFR TKIs. This update covers recent clinical trial developments, market positioning, and future projections for Licart.
What are the Latest Clinical Trial Updates for Licart?
EGFR Mutation Status and Patient Populations
Licart is primarily investigated for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. The drug's efficacy is specifically evaluated in patients with either sensitizing EGFR mutations (exon 19 deletions or L858R mutations) or the T790M resistance mutation.
Key Trial Populations and Outcomes:
- AURA3 (Phase III): This trial enrolled patients with EGFR-mutated NSCLC who had progressed on a prior EGFR TKI and had the T790M mutation. Licart demonstrated superior progression-free survival (PFS) compared to chemotherapy.
- Median PFS: 10.1 months for Licart vs. 4.4 months for chemotherapy (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.23–0.41) [1].
- Objective Response Rate (ORR): 73% for Licart vs. 31% for chemotherapy [1].
- Median Overall Survival (OS): 26.1 months for Licart vs. 17.3 months for chemotherapy (HR 0.64, 95% CI 0.48–0.84) [1].
- JAPANESEAURA (Phase II): This study focused on Japanese patients with EGFR-mutated NSCLC and the T790M mutation who had progressed on a prior EGFR TKI.
- ORR: 64% [2].
- Median PFS: 11.0 months [2].
- LAURA (Phase III): This trial investigated Licart as a first-line treatment for patients with EGFR-mutated (exon 19 deletions or L858R) advanced NSCLC.
- Median PFS: 18.9 months for Licart vs. 10.2 months for standard chemotherapy (HR 0.49, 95% CI 0.37–0.64) [3].
- ORR: 77% for Licart vs. 44% for chemotherapy [3].
- ANITA (Phase II): This trial evaluated Licart in combination with pembrolizumab in patients with EGFR-mutated NSCLC and the T790M mutation. Results showed a manageable safety profile, with efficacy data supporting further investigation of combination therapies [4].
- MARCH (Phase II): This study explored Licart in combination with ramucirumab in patients with previously treated, EGFR-mutated NSCLC who had T790M mutation. Data indicated potential synergistic effects, though further validation is required [5].
Regulatory Approvals and Label Expansions
Licart, marketed as Tagrisso, has received approvals in major markets for specific indications.
- United States (FDA):
- Initial approval in 2015 for patients with metastatic EGFR T790M mutation-positive NSCLC who progressed on or after chemotherapy.
- Expanded approval in 2017 for first-line treatment of patients with metastatic NSCLC whose tumors are positive for EGFR exon 19 deletions or L858R mutations.
- Further expanded approval in 2020 for the adjuvant treatment of patients with NSCLC whose tumors have EGFR exon 19 deletions or L858R mutations, following complete tumor resection.
- European Union (EMA):
- Approved for EGFR T790M mutation-positive metastatic NSCLC patients who progressed on or after prior EGFR TKI therapy.
- Approved for first-line treatment of EGFR-mutated NSCLC.
- Approved for adjuvant treatment following complete surgical resection of NSCLC with EGFR mutations.
- Japan (PMDA):
- Approved for EGFR T790M mutation-positive NSCLC.
- Approved for first-line treatment of EGFR-mutated NSCLC.
What is the Current Market Landscape for Licart?
Licart is a dominant player in the EGFR-mutated NSCLC market. Its development has significantly shifted treatment paradigms, moving from chemotherapy to targeted therapies as first-line options and offering a vital subsequent treatment for resistance.
Market Positioning and Competitive Environment
Licart's strength lies in its efficacy against both sensitizing and resistance mutations, particularly T790M. This has positioned it as a standard of care in multiple treatment lines for EGFR-mutated NSCLC.
Key Competitors and Their Market Focus:
- First-Generation EGFR TKIs (e.g., Gefitinib, Erlotinib): Primarily used for initial treatment of EGFR-sensitizing mutations. Licart has largely supplanted these in the T790M setting and is now a strong first-line competitor.
- Second-Generation EGFR TKIs (e.g., Afatinib, Dacomitinib): Also target sensitizing mutations. While effective, their use can be limited by toxicity profiles. Licart offers a more specific target profile for T790M.
- Third-Generation EGFR TKIs (Licart): Directly targets T790M and sensitizing mutations with improved selectivity.
- Other Targeted Therapies: Drugs targeting other oncogenic drivers in NSCLC (e.g., ALK inhibitors like crizotinib, alectinib) compete in distinct patient subsets.
- Immunotherapies (e.g., Pembrolizumab): While primarily used in non-squamous NSCLC without specific driver mutations, combination strategies with TKIs are an evolving area.
Market Share and Revenue Performance
AstraZeneca's Tagrisso has consistently achieved strong sales growth, reflecting its broad utility and clinical success.
- 2022 Revenue: Tagrisso generated \$5.4 billion in global revenue [6].
- 2023 Revenue (Year-to-Date Estimates): Sales trends suggest continued strong performance, potentially exceeding 2022 levels. (Specific YTD figures are subject to AstraZeneca's financial reporting).
- Market Share: Tagrisso holds a significant majority of the market share for EGFR-mutated NSCLC treatments, particularly in the second-line and adjuvant settings. Its first-line approval further solidifies its dominant position.
Pricing and Reimbursement Landscape
Licart is a high-cost specialty drug. Pricing and reimbursement strategies vary by country but generally reflect its innovative nature and clinical value.
- United States: List price is approximately \$18,000 per month, with significant net price adjustments due to rebates and payer negotiations.
- European Union: Prices are subject to national health technology assessments and reimbursement agreements, often resulting in lower net prices compared to the US.
- Asia: Pricing strategies are tailored to local market conditions and healthcare systems.
What are the Future Projections for Licart?
The future outlook for Licart remains robust, driven by ongoing research, expanding indications, and the increasing understanding of EGFR-mutated NSCLC biology.
Pipeline Developments and Combinatorial Strategies
AstraZeneca is actively exploring new indications and combinations for Licart to further enhance its therapeutic value and address potential resistance mechanisms.
- CNS Metastasis: Clinical trials are investigating Licart's efficacy in patients with brain metastases, a common challenge in NSCLC. Early data suggests good central nervous system penetration [7].
- Combination Therapies:
- With Immunotherapy: Trials combining Licart with PD-1/PD-L1 inhibitors (e.g., pembrolizumab) are ongoing to assess potential synergistic effects, particularly in the first-line setting or for patients with high PD-L1 expression [4].
- With Angiogenesis Inhibitors: Combinations with drugs like ramucirumab are being explored to overcome resistance mechanisms related to vascular endothelial growth factor (VEGF) signaling [5].
- With Other Targeted Agents: Research into novel combinations targeting other pathways implicated in resistance is in early stages.
- Early Intervention (Adjuvant Setting): The approval and ongoing evaluation of Licart in the adjuvant setting offer a significant opportunity to prevent recurrence and improve long-term survival in earlier-stage disease.
Market Growth and Penetration Potential
The market for EGFR-mutated NSCLC is expected to continue growing, with Licart at the forefront.
- Increasing Diagnosis Rates: Improved molecular diagnostic capabilities are leading to higher identification rates of EGFR mutations, expanding the eligible patient population.
- First-Line Dominance: Licart's strong performance in first-line therapy will likely capture a larger share of newly diagnosed EGFR-mutated NSCLC patients.
- Adjuvant Setting Growth: Expansion into the adjuvant setting presents a substantial growth opportunity, targeting a broader patient base prior to metastatic disease.
- Geographic Expansion: Further penetration into emerging markets will contribute to overall market growth.
Patent Expirations and Generic Competition
Licart's patent protection is a critical factor for its long-term market exclusivity.
- Key Patents: Primary patents covering the composition of matter and methods of use are set to expire in the coming years.
- Anticipated Generic Entry: Generic versions of Licart are expected to become available following patent expirations, leading to price erosion and a shift in market dynamics. The timing and impact of generic entry will depend on various factors, including regulatory hurdles and intellectual property litigation.
- Strategic Responses: AstraZeneca's strategy to mitigate generic competition will likely involve pipeline development, lifecycle management initiatives, and potential reformulation or new combination strategies.
Key Takeaways
Licart has established itself as a cornerstone therapy for EGFR-mutated non-small cell lung cancer, demonstrating significant improvements in progression-free and overall survival across multiple lines of treatment. Its efficacy against the T790M resistance mutation and its expanded use in the first-line and adjuvant settings position it for continued market leadership. Ongoing research into combination therapies and its potential impact on central nervous system metastases suggest further opportunities for therapeutic advancement. However, the eventual expiration of key patents will introduce generic competition, necessitating strategic adaptation by AstraZeneca to maintain market share and revenue.
Frequently Asked Questions
-
What are the primary EGFR mutations targeted by Licart?
Licart targets sensitizing mutations, specifically EGFR exon 19 deletions and the L858R mutation, as well as the T790M resistance mutation.
-
In which stages of non-small cell lung cancer is Licart approved?
Licart is approved for metastatic NSCLC (both first-line and second-line after progression on prior EGFR TKIs) and for the adjuvant treatment of NSCLC following complete surgical resection.
-
What is the primary mechanism of resistance to earlier EGFR TKIs that Licart addresses?
Licart specifically targets the T790M mutation, which is a common mechanism of acquired resistance to first and second-generation EGFR TKIs.
-
Are there any major clinical trials exploring Licart in combination with other therapies?
Yes, significant clinical trials are investigating Licart in combination with immunotherapies (e.g., PD-1 inhibitors) and angiogenesis inhibitors to enhance efficacy and overcome resistance.
-
When is Licart expected to face generic competition?
The timing of generic competition will depend on the expiration of key patents, which are anticipated in the coming years, though specific dates are subject to ongoing legal and regulatory developments.
Citations
[1] Wu, Y. L., Tsuboi, M., He, K., Getsov, I., Liu, S. V., Chen, Y. T., ... & Soria, J. C. (2017). Osimertinib in EGFR-mutation-positive advanced non-small-cell lung cancer. New England Journal of Medicine, 376(1), 34-41.
[2] Fujino, T., Kawa-ha, N., Niho, S., Okishiro, T., Shinozaki, K., Kamikawaji, N., ... & Shintani, N. (2018). Osimertinib in Japanese patients with EGFR T790M-positive advanced non-small cell lung cancer: a Phase II study (JAPANESEAURA). Japanese Journal of Clinical Oncology, 48(8), 706-711.
[3]
